Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Net Margin (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Net Margin data on record, last reported at 13.19% in Q3 2025.

  • For Q3 2025, Net Margin fell 483.0% year-over-year to 13.19%; the TTM value through Sep 2025 reached 8.72%, up 2967.0%, while the annual FY2024 figure was 5.49%, 248.0% down from the prior year.
  • Net Margin reached 13.19% in Q3 2025 per PLX's latest filing, up from 1.05% in the prior quarter.
  • Across five years, Net Margin topped out at 94.23% in Q4 2021 and bottomed at 176.89% in Q2 2021.
  • Average Net Margin over 5 years is 25.04%, with a median of 25.15% recorded in 2022.
  • Peak YoY movement for Net Margin: crashed -13871bps in 2021, then soared 11596bps in 2022.
  • A 5-year view of Net Margin shows it stood at 94.23% in 2021, then crashed by -140bps to 37.25% in 2022, then plummeted by -54bps to 57.28% in 2023, then skyrocketed by 162bps to 35.65% in 2024, then tumbled by -63bps to 13.19% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 13.19% in Q3 2025, 1.05% in Q2 2025, and 35.79% in Q1 2025.